BMPs and their clinical potentials

키워드

참고문헌 (211)

1. Wagner, D. O, "BMPs: from bone to body morphogenetic proteins", Sci. Signal, 3, pp.mr1~ (2010)
2. Reddi, A. H, "BMPs: from bone morphogenetic proteins to body morphogenetic proteins", Cytokine. Growth. Factor. Rev, 16, pp.249~250 (2005)
3. Satterfield, M. C, "Brown adipose tissue growth and development: significance and nutritional regulation", Front. Biosci, 16, pp.1589~1608 (2011)
4. Kopelman, P. G, "Obesity as a medical problem", Nature, 404, pp.635~643 (2000)
5. Hsu, I. R, "Metabolic syndrome, hyperinsulinemia, and cancer", Am J. Clin. Nutr, 86, pp.s867~s871 (2007)
6. Craft,S, "Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment", Curr. Alzheimer. Res, 4, pp.147~152 (2007)
7. Cornier, M. A, "The metabolic syndrome", Endocr. Rev, 29, pp.777~822 (2008)
8. Hammond, R. A, "The economic impact of obesity in the United States", Diabetes. Metab. Syndr. Obes, 3, pp.285~295 (2010)
9. Zamani, N, "Emerging roles for the transforming growth factor-{beta} superfamily in regulating adiposity and energy expenditure", Endocr. Rev, 32, pp.387~403 (2011)
10. Snow, V, "Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians", Ann. Intern. Med, 142, pp.525~531 (2005)
11. Colman, E, "Anorectics on trial: a half century of federal regulation of prescription appetite suppressants", Ann. Intern. Med, 143, pp.380~385 (2005)
12. Gesta, S, "Developmental origin of fat: tracking obesity to its source", Cell, 131, pp.242~256 (2007)
13. Martinsson, A, "Hypertrophy and hyperplasia of human adipose tissue in obesity", Pol. Arch. Med. Wewn, 42, pp.481~486 (1969)
14. Shepherd, P. R, "Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue", J. Biol. Chem, 268, pp.22243~22246 (1993)
15. Otto, T. C, "Adipose development: from stem cell to adipocyte", Crit. Rev. Biochem. Mol. Biol, 40, pp.229~242 (2005)
16. Tang, Q. Q, "Commitment of C3H10T1", 2 pluripotent stem cells to the adipocyte lineage, 2004, pp.101, 9607~9611
17. Tseng, Y. H, "New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure", Nature, 454, pp.1000~1004 (2008)
18. 김재우, "Stable stem cell commitment to the adipocyte lineage by inhibition of DNA methylation: Role of the BMP-4 gene", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 103(35), pp.13022~13027, NATL ACAD SCIENCES
19. Dani, C, "Differentiation of embryonic stem cells into adipocytes in vitro", J. Cell. Sci, 110(Pt 11), pp.1279~1285 (1997)
20. Cell Cycle, "A role for bone morphogenetic protein-4 in adipocyte development", Cell Cycle, 6, pp.385~389 (2007)
21. Ji, X, "Patterns of gene expression associated with BMP-2-induced osteoblast and adipocyte differentiation of mesenchymal progenitor cell 3T3-F442A", J. Bone Miner. Metab, 18, pp.132~139 (2000)
22. Sottile, V, "Bone morphogenetic protein-2 stimulates adipogenic differentiation of mesenchymal precursor cells in synergy with BRL 49653 (rosiglitazone)", FEBS Lett, 475, pp.201~204 (2000)
23. Hata, K, "Differential roles of Smad1 and p38 kinase in regulation of peroxisome proliferator-activating receptor gamma during bone morphogenetic protein 2-induced adipogenesis", Mol. Biol. Cell, 14, pp.545~555 (2003)
24. Jin, W, "Schnurri-2 controls BMP-dependent adipogenesis via interaction with Smad proteins", Dev. Cell, 10, pp.461~471 (2006)
25. Chen, D, "Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages", J. Cell. Biol, 142, pp.295~305 (1998)
26. Sebald, W, "Molecular recognition in bone morphogenetic protein (BMP)", receptor interaction, 2004, pp.385, 697~710
27. Schulz, T. J, "Emerging role of bone morphogenetic proteins in adipogenesis and energy metabolism", Cytokine. Growth. Factor. Rev, 20, pp.523~531 (2009)
28. Bottcher, Y, "Adipose tissue expression and genetic variants of the bone morphogenetic protein receptor 1A gene (BMPR1A) are associated with human obesity", Diabetes, 58, pp.2119~2128 (2009)
29. Wu, Y, "Downregulated expression of the secreted glycoprotein follistatin-like 1 (Fstl1) is a robust hallmark of preadipocyte to adipocyte conversion", Mech. Dev, 127, pp.183~202 (2010)
30. Allen, D. L, "Myostatin, activin receptor IIb, and follistatin- like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice", Am. J. Physiol. Endocrinol. Metab, 294, pp.E918~E927 (2008)
31. Chen, T. L, "Human BMP-7", OP-1 induces the growth and differentiation of adipocytes and osteoblasts in bone marrow stromal cell cultures, 2001, pp.82, 187~199
32. Neumann, K, "BMP7 promotes adipogenic but not osteo-", chondrogenic differentiation of adult human bone marrow-derived stem cells in high-density micro-mass culture, 2007, pp.102, 626~637
33. Richard, D, "Determinants of brown adipocyte development and thermogenesis", Int. J. Obes, 34(suppl 2), pp.S59~S66 (2010)
34. Cypess, A. M, "Identification and importance of brown adipose tissue in adult humans", N. Engl. J. Med, 360, pp.1509~1517 (2009)
35. Virtanen, K. A, "Functional brown adipose tissue in healthy adults", N. Engl. J. Med, 360, pp.1518~1525 (2009)
36. Saito, M, "High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity", Diabetes, 58, pp.1526~1531 (2009)
37. Zingaretti, M. C, "The presence of UCP1 demonstrates that metabolically active adipose tissue in the neck of adult humans truly represents brown adipose tissue", FASEB. J, 23, pp.3113~3120 (2009)
38. Harris,M.I, "Diabetes in America: epidemiology and scope of the problem", Diabetes Care, 21(suppl 3), pp.c11~c14 (1998)
39. Taylor, S. I, "Deconstructing type 2 diabetes", Cell, 97, pp.9~12 (1999)
40. Saltiel, A. R, "New perspectives into the molecular pathogenesis and treatment of type 2 diabetes", Cell, 104, pp.517~529 (2001)
41. Chen, J. W, "Limitations to subcutaneous insulin administration in type 1 diabetes", Diabetes Obes. Metab, 5, pp.223~233 (2003)
42. Chen, W, "Insulin-like growth factor (IGF)-I", IGF-binding protein-3 complex: therapeutic efficacy and mechanism of protection against type 1 diabetes, 2004, pp.145, 627~638
43. Tobin, J. F, "Bone morphogenetic proteins and growth differentiation factors as drug targets in cardiovascular and metabolic disease", Drug. Discov Today, 11, pp.405~411 (2006)
44. Miller, A. F, "Bone morphogenetic protein-9. An autocrine", paracrine cytokine in the liver, 2000, pp.275, 17937~17945
45. Caperuto, L. C, "Modulation of bone morphogenetic protein-9 expression and processing by insulin, glucose, and glucocorticoids: possible candidate for hepatic insulin-sensitizing substance", Endocrinology, 149, pp.6326~6335 (2008)
46. Lautt,W.W, "The HISS story overview: a novel hepatic neurohumoral regulation of peripheral insulin sensitivity in health and diabetes", Can. J. Physiol. Pharmacol, 77, pp.553~562 (1999)
47. Bidart, M, "BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain", Cell. Mol. Life. Sci (2011)
48. Anhe, F. F, "Smad5 regulates Akt2 expression and insulin- induced glucose uptake in L6 myotubes", Mol. Cell. Endocrinol, 319, pp.30~38 (2010)
49. Song, J. J, "Bone morphogenetic protein-9 binds to liver cells and stimulates proliferation", Endocrinology, 136, pp.4293~4297 (1995)
50. Chen, C, "An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis", Nat. Biotechnol, 21, pp.294~301 (2003)
51. Wang, J, "BMP signaling in congenital heart disease: new developments and future directions", Birth. Defects. Res. A. Clin. Mol. Teratol, 91, pp.441~448 (2011)
52. Lowery, J. W, "BMP signaling in vascular development and disease", Cytokine Growth Factor Rev, 21, pp.287~298 (2010)
53. Chen, N. X, "Arterial calcification in diabetes", Curr. Diab. Rep, 3, pp.28~32 (2003)
54. Liu, Y, "Signalling pathways and vascular calcification", Front. Biosci, 16, pp.1302~1314 (2011)
55. Rennenberg, R. J, "Arterial calcifications", J. Cell. Mol. Med, 14, pp.2203~2210 (2010)
56. Corriere, M. A, "Endothelial Bmp4 is induced during arterial remodeling: effects on smooth muscle cell migration and proliferation", J. Surg. Res, 145, pp.142~149 (2008)
57. Bostrom, K, "Bone morphogenetic protein expression in human atherosclerotic lesions", J. Clin. Invest, 91, pp.1800~1809 (1993)
58. Sorescu, G. P, "Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response", J. Biol. Chem, 278, pp.31128~31135 (2003)
59. Cheng, S. L, "MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors", J. Biol. Chem, 278, pp.45969~94977 (2003)
60. Tobin,M.J.(2003)Chronic obstructive pulmonary disease,pollution,pulmonary vascular disease,transplantation,pleural disease,and lung cancer in AJRCCM, "Chronic obstructive pulmonary disease, pollution, pulmonary vascular disease, transplantation, pleural disease, and lung cancer in AJRCCM 2002", Am. J. Respir. Crit. Care. Med, 167, pp.356~370 (2002)
61. Zebboudj, A. F, "Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2", J. Biol. Chem, 277, pp.4388~4394 (2002)
62. Yao, Y, "Regulation of bone morphogenetic protein-4 by matrix GLA protein in vascular endothelial cells involves activin-like kinase receptor 1", J. Biol. Chem, 281, pp.33921~33930 (2006)
63. Dhore, C. R, "Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques", Arterioscler. Thromb. Vasc. Biol, 21, pp.1998~2003 (2001)
64. Luo, G, "Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein", Nature, 386, pp.78~81 (1997)
65. Sweatt, A, "Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats", J. Thromb. Haemost, 1, pp.178~185 (2003)
66. Hur, D. J, "A novel MGP mutation in a consanguineous family: review of the clinical and molecular characteristics of Keutel syndrome", Am. J. Med. Genet. A, 135, pp.36~40 (2005)
67. Hruska, K. A, "Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction", Am. J. Physiol. Renal. Physiol, 279, pp.F130~F143 (2000)
68. Vukicevic, S, "Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat", J. Clin. Invest, 102, pp.202~214 (1998)
69. Simic, P, "Bone morphogenetic proteins in development and homeostasis of kidney", Cytokine. Growth. Factor. Rev, 16, pp.299~308 (2005)
70. Zeisberg, M, "BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury", Nat. Med, 9, pp.964~968 (2003)
71. Davies, M. R, "BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure", J. Am. Soc. Nephrol, 14, pp.1559~1567 (2003)
72. Li, T, "Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease", Curr. Opin. Nephrol. Hypertens, 13, pp.417~422 (2004)
73. McAllister, K. A, "Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1", Nat. Genet, 8, pp.345~351 (1994)
74. Johnson, D. W, "Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2", Nat. Genet, 13, pp.189~195 (1996)
75. Gallione, C. J, "SMAD4 mutations found in unselected HHT patients", J. Med. Genet, 43, pp.793~797 (2006)
76. Sabba, C, "Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers", J. Thromb. Haemost, 5, pp.1149~1157 (2007)
77. Oh, S. P, "Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis", Proc. Natl. Acad. Sci. U.S.A, 97, pp.2626~2631 (2000)
78. Urness, L. D, "Arteriovenous malformations in mice lacking activin receptor- like kinase-1", Nat. Genet, 26, pp.328~331 (2000)
79. Roman, B. L, "Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels", Development, 129, pp.3009~3019 (2002)
80. Li, D. Y, "Defective angiogenesis in mice lacking endoglin", Science, 284, pp.1534~1537 (1999)
81. Liu, D, "Dosage-dependent requirement of BMP type II receptor for maintenance of vascular integrity", Blood, 110, pp.1502~1510 (2007)
82. Arthur, H. M, "Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development", Dev. Biol, 217, pp.42~53 (2000)
83. Srinivasan, S, "A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2", Hum. Mol. Genet, 12, pp.473~482 (2003)
84. 이영재, "ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2", BLOOD, 111(2), pp.633~642, AMER SOC HEMATOLOGY
85. Bourdeau, A, "Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia", Trends. Cardiovasc. Med, 10, pp.279~285 (2000)
86. Bourdeau, A, "Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1", Am. J. Pathol, 156, pp.911~923 (2000)
87. Mitchell, A, "Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia", Liver. Transpl, 14, pp.210~213 (2008)
88. Cruikshank, R. P, "Bevacizumab and hereditary haemorrhagic telangiectasia", Med. J. Aust, 194, pp.324~325 (2011)
89. Machado, R. D, "Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension", Hum. Mutat, 278, pp.121~132 (2006)
90. Machado, R. D, "Genetics and genomics of pulmonary arterial hypertension", J. Am. Coll. Cardiol, 54, pp.S32~S42 (2009)
91. Lane, K. B, "Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension", Nat. Genet, 26, pp.81~84 (2000)
92. Thomson, J. R, "Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family", J. Med. Genet, 37, pp.741~745 (2000)
93. Simonneau, G, "Clinical classification of pulmonary hypertension", J. Am. Coll. Cardiol, 43, pp.S5~S12 (2004)
94. Du, L, "Signaling molecules in nonfamilial pulmonary hypertension", N. Engl. J. Med, 348, pp.500~509 (2003)
95. Atkinson, C, "Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor", Circulation, 105, pp.1672~1678 (2002)
96. Humbert, M, "BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives", Eur. Respir. J, 20, pp.518~523 (2002)
97. Lowery, J. W, "ID family protein expression and regulation in hypoxic pulmonary hypertension", Am. J. Physiol. Regul. Integr. Comp. Physiol, 299, pp.R1463~R1477 (2010)
98. Foletta, V. C, "Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1", J. Cell. Biol, 162, pp.1089~1098 (2003)
99. Frank, D. B, "Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature", Am. J. Physiol. Lung. Cell. Mol. Physiol, 294, pp.L98~L109 (2008)
100. 이영재, "Genetic ablation of the Bmpr2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension", CIRCULATION, 118, pp.722~730, LIPPINCOTT WILLIAMS & WILKINS
101. Song, Y, "Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice", Am. J. Physiol. Heart Circ. Physiol, 295, pp.H677~H690 (2008)
102. Song, Y, "Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice", Circulation, 112, pp.553~562 (2005)
103. West, J, "Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension", Adv. Exp. Med. Biol, 661, pp.265~278 (2010)
104. Reynolds,P.N, "Gene therapy for pulmonary hypertension: prospects and challenges", Expert. Opin. Biol. Ther, 11, pp.133~143 (2011)
105. Reynolds,P.N, "Viruses in pharmaceutical research: pulmonary vascular disease", Mol. Pharm, 8, pp.56~64 (2011)
106. Yuan, J. X, "Pathogenesis of pulmonary arterial hypertension: the need for multiple hits", Circulation, 111, pp.534~538 (2005)
107. Baliga, R. S, "New perspectives for the treatment of pulmonary hypertension", Br. J. Pharmacol, 163, pp.125~140 (2011)
108. Pardali, E, "Transforming growth factor-beta signaling and tumor angiogenesis", Front Biosci, 14, pp.4848~4861 (2009)
109. Massague, J, "TGFbeta in Cancer", Cell, 134, pp.215~230 (2008)
110. Singh, A, "The Yin and Yang of bone morphogenetic proteins in cancer", Cytokine. Growth. Factor. Rev, 21, pp.299~313 (2010)
111. Wharton, K, "TGFbeta family signaling: novel insights in development and disease", Development, 136, pp.3691~3697 (2009)
112. Walsh, D. W, "Extracellular BMP-antagonist regulation in development and disease: tied up in knots", Trends. Cell Biol, 20, pp.244~256 (2010)
113. Kleeff, J, "Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo", Gastroenterology, 116, pp.1202~1216 (1999)
114. Herrera, B, "Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2", Smad1, Cancer Res, pp.2009, 69[DOI]
115. Alarmo, E. L, "BMP7 influences proliferation, migration, and invasion of breast cancer cells", Cancer Lett, 275, pp.35~43 (2009)
116. Arnold, S. F, "Identification of bone morphogenetic proteins and their receptors in human breast cancer cell lines: importance of BMP2", Cytokine, 11, pp.1031~1037 (1999)
117. Ro, T. B, "Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells", Oncogene, 23, pp.3024~3032 (2004)
118. Piccirillo, S. G, "Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour- initiating cells", Nature, 444, pp.761~765 (2006)
119. Du, J, "Bone morphogenetic protein 6 inhibit stress-induced breast cancer cells apoptosis via both Smad and p38 pathways", J. Cell. Biochem, 103, pp.1584~1597 (2008)
120. Johnsen, I. K, "Bone morphogenetic proteins 2 and 5 are down-regulated in adrenocortical carcinoma and modulate adrenal cell proliferation and steroidogenesis", Cancer Res, 69, pp.5784~5792 (2009)
121. Quan, G. M, "Anti-angiogenic therapy for osteosarcoma", Cancer Metastasis Rev, 25, pp.707~713 (2006)
122. Hanahan, D, "Hallmarks of cancer: the next generation", Cell, 144, pp.646~674 (2011)
123. Bergers, G, "Tumorigenesis and the angiogenic switch", Nat. Rev. Cancer, 3, pp.401~410 (2003)
124. Carmeliet, P, "Angiogenesis in life, disease and medicine", Nature, 438, pp.932~936 (2005)
125. Carmeliet, P, "VEGF as a key mediator of angiogenesis in cancer", Oncology, 69(suppl 3), pp.4~10 (2005)
126. David, L, "Emerging role of bone morphogenetic proteins in angiogenesis", Cytokine. Growth. Factor Rev, 20, pp.203~212 (2009)
127. Langenfeld, E. M, "Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors", Mol. Cancer Res, 2, pp.141~149 (2004)
128. Valdimarsdottir, G, "Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells", Circulation, 106, pp.2263~2270 (2002)
129. Raida, M, "Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis", J. Cancer Res. Clin. Oncol, 131, pp.741~750 (2005)
130. Peng, H, "VEGF improves, whereas sFlt1 inhibits, BMP2-induced bone formation and bone healing through modulation of angiogenesis", J. Bone Miner. Res, 20, pp.2017~2027 (2005)
131. Rothhammer, T, "Functional implication of BMP4 expression on angiogenesis in malignant melanoma", Oncogene, 26, pp.4158~4170 (2007)
132. Smadja, D. M, "Bone morphogenetic proteins 2 and 4 are selectively expressed by late outgrowth endothelial progenitor cells and promote neoangiogenesis. Arterioscler", Thromb. Vasc. Biol, 28, pp.2137~2143 (2008)
133. Bieniasz, M, "The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients", Lung Cancer, 66, pp.319~326 (2009)
134. Moreno-Miralles, I, "New insights into bone morphogenetic protein signaling: focus on angiogenesis", Curr. Opin. Hematol, 16, pp.195~201 (2009)
135. Nimmagadda, S, "BMP4 and noggin control embryonic blood vessel formation by antagonistic regulation of VEGFR-2 (Quek1) expression", Dev. Biol, 280, pp.100~110 (2005)
136. Scharpfenecker, M, "BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGFstimulated angiogenesis", J. Cell. Sci, 120, pp.964~972 (2007)
137. David, L, "Bone morphogenetic protein-9 is a circulating vascular quiescence factor", Circ. Res, 102, pp.914~922 (2008)
138. Liu, Z, "VEGF and inhibitors of TGFbeta type-I receptor kinase synergistically promote blood-vessel formation by inducing alpha5-integrin expression", J. Cell. Sci, 122, pp.3294~3302 (2009)
139. Mitchell, D, "ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth", Mol. Cancer. Ther, 9, pp.379~388 (2010)
140. Mitchell, D. C, "Anti-angiogenic therapy: adapting strategies to overcome resistant tumors", J. Cell Biochem, 111, pp.543~553 (2010)
141. Hay, E. D, "Transformations between epithelium and mesenchyme: normal, pathological, and experimentally induced", Am. J. Kidney. Dis, 26, pp.678~690 (1995)
142. Klymkowsky, M. W, "Epithelialmesenchymal transition: a cancer researcher's conceptual friend and foe", Am. J. Pathol, 174, pp.1588~1593 (2009)
143. Polyak, K, "Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits", Nat. Rev. Cancer, 9, pp.265~273 (2009)
144. Thiery, J. P, "Epithelial-mesenchymal transitions in development and disease", Cell, 139, pp.871~890 (2009)
145. Yilmaz, M, "EMT, the cytoskeleton, and cancer cell invasion", Cancer. Metastasis. Rev, 28, pp.15~33 (2009)
146. Barrallo-Gimeno, A, "The Snail genes as inducers of cell movement and survival: implications in development and cancer", Development, 132, pp.3151~3161 (2005)
147. Sethi, N, "Dysregulation of developmental pathways in bone metastasis", Bone, 48, pp.16~22 (2011)
148. Ma, L, "Bmp2 is essential for cardiac cushion epithelial-mesenchymal transition and myocardial patterning", Development, 132, pp.5601~5611 (2005)
149. Theriault, B. L, "BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells", Carcinogenesis, 28, pp.1153~1162 (2007)
150. Feeley, B. T, "Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions", Bone, 38, pp.154~166 (2006)
151. Clement, J. H, "Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone independent growth of breast carcinoma cells", Int. J. Oncol, 27, pp.601~407 (2005)
152. Katsuno, Y, "Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway", Oncogene, 27, pp.6322~6333 (2008)
153. Moreau, J. E, "Tissue-engineered bone serves as a target for metastasis of human breast cancer in a mouse model", Cancer Res, 67, pp.10304~10308 (2007)
154. Deng, H, "Bone morphogenetic protein-4 inhibits heat-induced apoptosis by modulating MAPK pathways in human colon cancer HCT116 cells", Cancer Lett, 256, pp.207~217 (2007)
155. Kang, M. H, "BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)", Akt pathway, 2010, pp.316(1), 24~37[DOI]
156. Orr, F. W, "Tumor-bone interactions in skeletal metastasis", Clin. Orthop. Relat. Res, 312, pp.19~33 (1995)
157. Mundy, G. R, "Mechanisms of bone metastasis", Cancer, 80, pp.1546~1556 (1997)
158. Jemal, A, "Cancer statistics, 2009", Cancer. J. Clin, 59, pp.225~249 (2009)
159. Coleman, R. E, "Skeletal complications of malignancy", Cancer, 80, pp.1588~1594 (1997)
160. Galasko, C. S, "Skeletal metastases", Clin. Orthop. Relat. Res, 210, pp.18~30 (1986)
161. Bussard, K. M, "The bone microenvironment in metastasis; what is special about bone", Cancer Metastasis. Rev, 27, pp.41~55 (2008)
162. Davies, S. R, "Bone morphogenetic proteins 1 to 7 in human breast cancer, expression pattern and clinical", prognostic relevance, 2008, pp.7, 327~338
163. McMurtry, I. F, "Introduction: pre- and postnatal lung development, maturation, and plasticity", Am. J. Physiol. Lung. Cell. Mol. Physiol, 282, pp.L341~L344 (2002)
164. Mundy,G.R, "Metastasis to bone: causes, consequences and therapeutic opportunities", Nat. Rev. Cancer, 2, pp.584~593 (2002)
165. Ye, L, "Bone morphogenetic protein and bone metastasis, implication and therapeutic potential", Front Biosci, 16, pp.865~897 (2011)
166. Roodman, G. D, "Mechanisms of bone metastasis", N. Engl. J. Med, 350, pp.1655~1664 (2004)
167. Lu, X, "Epidermal growth factor signalling and bone metastasis", Br. J. Cancer, 102, pp.457~461 (2010)
168. Kang, Y, "A multigenic program mediating breast cancer metastasis to bone", Cancer Cell, 3, pp.537~549 (2003)
169. Mastro, A. M, "The skeleton as a unique environment for breast cancer cells", Clin. Exp. Metastasis, 20, pp.275~284 (2003)
170. Schneider, A, "Bone turnover mediates preferential localization of prostate cancer in the skeleton", Endocrinology, 146, pp.1727~1736 (2005)
171. Senta, H, "Cell responses to bone morphogenetic proteins and peptides derived from them: biomedical applications and limitations", Cytokine. Growth. Factor. Rev, 20, pp.213~222 (2009)
172. Graham, T. R, "Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells", Cancer Sci, 101, pp.103~111 (2010)
173. Rucci, N, "Osteomimicry: how tumor cells try to deceive the bone", Front. Biosci, 2, pp.907~915 (2010)
174. Bailey, J. M, "Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins", J. Cell. Biochem, 102, pp.829~839 (2007)
175. Kalluri, R, "Fibroblasts in cancer", Nat. Rev. Cancer, 6, pp.392~401 (2006)
176. Cooper, C. R, "Stromal factors involved in prostate carcinoma metastasis to bone", Cancer, 97, pp.739~747 (2003)
177. Spradling, A, "Stem cells find their niche", Nature, 414, pp.98~104 (2001)
178. Blanco Calvo, M, "Biology of BMP signalling and cancer", Clin. Transl. Oncol, 11, pp.126~137 (2009)
179. Qiao, B, "Disclosure of a stem cell phenotype in an oral squamous cell carcinoma cell line induced by BMP-4 via an epithelial-mesenchymal transition", Oncol. Rep, 26, pp.455~461 (2011)
180. Mani, S. A, "The epithelial-mesenchymal transition generates cells with properties of stem cells", Cell, 133, pp.704~715 (2008)
181. Carlson, M. E, "Regulating the Notch pathway in embryonic, adult and old stem cells", Curr. Opin. Pharmacol, 7, pp.303~309 (2007)
182. Zhang, M, "Stem cells in the etiology and treatment of cancer", Curr. Opin. Genet. Dev, 16, pp.60~64 (2006)
183. Katoh, M, "Network of WNT and other regulatory signaling cascades in pluripotent stem cells and cancer stem cells", Curr. Pharm. Biotechnol, 12, pp.160~170 (2011)
184. Katoh, M, "Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis", Stem. Cell. Rev, 3, pp.30~38 (2007)
185. Lombardo, Y, "Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice", Gastroenterology, 140, pp.297~309 (2011)
186. Yauch, R. L, "A paracrine requirement for hedgehog signalling in cancer", Nature, 455, pp.406~410 (2008)
187. Von Hoff, D. D, "Inhibition of the hedgehog pathway in advanced basal-cell carcinoma", N. Engl. J. Med, 361, pp.1164~1172 (2009)
188. Yu, P. B, "Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism", Nat. Chem. Biol, 459, pp.33~41 (2008)
189. Jiang, W. G, "Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome", Mol. Cancer, 7, pp.71~ (2008)
190. Ye, L, "Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4", Mol. Cancer Res, 6, pp.1594~1606 (2008)
191. Ong, K. L, "Off-label use of bone morphogenetic proteins in the United States using administrative data", Spine, 35, pp.1794~1800 (2010)
192. Thawani, J. P, "Bone morphogenetic proteins and cancer: review of the literature", Neurosurgery, 66, pp.233~246 (2010)
193. Poynton, A. R, "Safety profile for the clinical use of bone morphogenetic proteins in the spine", Spine, 27, pp.S40~S48 (2002)
194. Sundaresan, N, "Tumors of the osseous spine", J. Neurooncol, 69, pp.273~290 (2004)
195. Benglis, D, "A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery", Neurosurgery, 62, pp.423~431 (2008)
196. Nakashima, M, "The application of bone morphogenetic proteins to dental tissue engineering", Nat. Biotechnol, 21, pp.1025~1032 (2003)
197. Seeherman, H, "Delivery of bone morphogenetic proteins for orthopedic tissue regeneration", Cytokine. Growth. Factor. Rev, 16, pp.329~345 (2005)
198. Bessa, P. C, "Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts)", J. Tissue. Eng. Regen. Med, 2, pp.1~13 (2008)
199. Wozney, J. M, "regulators of bone formation: molecular clones and activities", Science, 242, pp.1528~1534 (1988)
200. Schmidmaier, G, "Carrier systems and application of growth factors in orthopaedics", Injury, 39(suppl 2), pp.S37~S43 (2008)
201. Gottfried, O. N, "Mesenchymal stem cell and gene therapies for spinal fusion", Neurosurgery, 63, pp.380~391 (2008)
202. Alaoui-Ismaili, M. H, "Design of second generation therapeutic recombinant bone morphogenetic proteins", Cytokine. Growth. Factor. Rev, 20, pp.501~507 (2009)
203. Allendorph, G. P, "Designer TGF-beta superfamily ligands with diversified functionality", PLoS One (2011)
204. Saito, A, "Activation of osteo-progenitor cells by a novel synthetic peptide derived from the bone morphogenetic protein-2 knuckle epitope", Biochim. Biophys. Acta, 1651, pp.60~67 (2003)
205. Bergeron, E, "Differentiation of preosteoblasts using a delivery system with BMPs and bioactive glass microspheres", J. Mater. Sci. Mater. Med, 18, pp.255~263 (2007)
206. Geiger, M, "Collagen sponges for bone regeneration with rhBMP-2", Adv. Drug. Deliv. Rev, 55, pp.1613~1629 (2003)
207. Uludag, H, "rhBMP-collagen sponges as osteoinductive devices: effects of in vitro sponge characteristics and protein pI on in vivo rhBMP pharmacokinetics", Ann. N. Y. Acad. Sci, 875, pp.369~378 (1999)
208. Kempen, D. H, "Retention of in vitro and in vivo BMP-2 bioactivities in sustained delivery vehicles for bone tissue engineering", Biomaterials, 29, pp.3245~3252 (2008)
209. Zambaux, M. F, "Influence of experimental parameters on the characteristics of poly (lactic acid) nanoparticles prepared by a double emulsion method", J. Control. Release, 50, pp.31~40 (1998)
210. Franceschi, R. T, "Biological approaches to bone regeneration by gene therapy", J. Dent. Res, 84, pp.1093~1103 (2005)
211. Li, H. Y, "Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy", J. Drug. Target, 11, pp.425~432 (2003)

관련 논문AI추천